A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
Clinical trial NCT03699241 · COMPLETED
Trial details
- NCT number
- NCT03699241
- Sponsor
- International AIDS Vaccine Initiative
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-03
- Primary completion
- 2023-03-21
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.